IL-31 a TH2 Cytokine Involved in Immunity and Inflammation

Castellani, M.L.; Felaco, Paolo; Galzio, Renato; Tripodi, Domenico; Toniato, E; Lutiis, Maria Anna De; Fulcheri, Mario; Caraffa, Auro; Antinolfi, Pierluigi; Tetè, Stefano; Felaco, Mario; Conti, Francesca; Pandolfi, Franco; Theoharides, Theoharis C.; Shaik-Dasthagirisaheb, Y.B.

doi:10.1177/039463201002300304

Cited by 24 publications

(27 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both IL-15 and IL-27 are associated with a negative regulatory role on Th17 responses (26, 27) and were significantly increased in MS relapse, but only IL-27 was elevated in MS remission compared to control samples. IL-28A and IL-31 are key mediators in T-cell mediated inflammatory diseases (28, 29) and were significantly elevated in sera from both relapse and remission compared to sera from control samples.…”

Section: Resultsmentioning

confidence: 99%

T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis

Cala

Moseley

Steele

et al. 2016

Journal of Neuroimmunology

View full text Add to dashboard Cite

Although Multiple Sclerosis is predominantly regarded as a disease of young adulthood, up to five percent of MS patients are diagnosed prior to age eighteen. The predominant form of MS is relapsing-remitting characterized by exacerbations of symptoms followed by periods of remission. The majority of disease modifying drugs target T cell proliferation or block migration into the central nervous system. Although these treatments reduce relapses, disease progression still occurs, warranting therapeutic strategies that protect the CNS. Biomarkers to indicate relapses would facilitate a personalized approach for add-on therapies that protect the CNS. A multiplex cytokine bead array was performed to detect T cell associated cytokines in sera from patients 6–20 years of age with pediatric onset MS clinically diagnosed in relapse or remission compared to healthy control patients. Of the 25 cytokines evaluated, 17 were increased in patients clinically diagnosed in relapse compared to sera from control patients in contrast to only 9 cytokines in the clinically diagnosed remission group. Furthermore, a linear regression analysis of cytokine levels in the remission population showed 12 cytokines to be statistically elevated as a function of disease duration, with no effect observed in the relapse population. To further explore this concept, we used a multivariable stepwise discriminate analysis and found that the following four cytokines (IL-10, IL-21, IL-23, and IL-27) are not only a significant predictor for MS, but have important predictive value in determining a relapse. Since IL-10 and IL-27 are considered anti-inflammatory and IL-21 and IL-23 are pro-inflammatory, ratios of these cytokines were evaluated using a Duncan’s multiple range test. Of the six possible combinations, increased ratios of IL-10:IL-21, IL-10:IL-23, and IL-10:IL-27 were significant suggesting levels of IL-10 to be a driving force in predicting a relapse.

show abstract

Section: Resultsmentioning

confidence: 99%

T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis

Cala

Moseley

Steele

et al. 2016

Journal of Neuroimmunology

View full text Add to dashboard Cite

show abstract

“…The enhanced expression of IL-31 has been associated with a number of diseases, including allergy and inflammatory bowel disease [59] . IL-31 coordinates Bas [63] , MC [64] , DC [21] MC [47] , T cells [155] MC [51] , Bas [53] , EC [29] , Th2 cells [31] Eos, Th2 cells, MC, Bas [54] EC, Eos, Bas, MC [56] Th2 cells [60] , MC [61] EC [21] MC [65] , EC [21] , Bas [53] , Th2 cells [66] Bind to high affinity IgE receptor FcεRI forming sensitized MC and Bas. Cross links 2 adjacent IgEs on sensitized MC or Bas can activate them to release proinflammatory mediators or cytokines, which initiates clinical manifestation of allergy.…”

Section: Molecular Messengers Of Allergymentioning

confidence: 99%

“…IL-31 is primarily produced in Th2 [60] and mast cells [61] , suggesting a role in allergic diseases.…”

Section: Wwwnaturecom/aps He Sh Et Almentioning

confidence: 99%

Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis

Zhang

Zeng

et al. 2013

Acta Pharmacol Sin

View full text Add to dashboard Cite

The current definition of allergy is a group of IgE-mediated diseases. However, a large portion of patients with clinical manifestations of allergies do not exhibit elevated serum levels of IgE (sIgEs). In this article, three key factors, ie soluble allergens, sIgEs and mast cells or basophils, representing the causative factors, messengers and primary effector cells in allergic inflammation, respectively, were discussed. Based on current knowledge on allergic diseases, we propose that allergic diseases are a group of diseases mediated through activated mast cells and/or basophils in sensitive individuals, and allergic diseases include four subgroups: (1) IgE dependent; (2) other immunoglobulin dependent; (3) non-immunoglobulin mediated; (4) mixture of the first three subgroups. According to our proposed definition, pseudo-allergic-reactions, in which mast cell or basophil activation is not mediated via IgE, or to a lesser extent via IgG or IgM, should be non-IgE-mediated allergic diseases. Specific allergen challenge tests (SACTs) are gold standard tests for diagnosing allergies in vivo, but risky. The identification of surface membrane activation markers of mast cells and basophils (CD203c, CCR3, CD63, etc) has led to development of the basophil activation test (BAT), an in vitro specific allergen challenge test (SACT). Based on currently available laboratory allergy tests, we here propose a laboratory examination procedure for allergy.

show abstract

“…Рецепторы к лиганду CCL2 обнаруживаются на отдельных популяциях лейкоцитов, в том числе и базофилах, рецепторы к CХCL8 находятся на нейтрофилах. Активация данных рецепторов приводит к активации клеток у пациентов с хроническим течением крапивни-цы [29].…”

Section: ) иммунная активация тучных клеток при хро-нической крапивницеunclassified

Chronic Urticarial in Childhood. Immune Pathology of Chronic Urticarial in Children (Part I)

2014

View full text Add to dashboard Cite

Резюме. В данной части обзора рассмотрены распространенность, генетические факторы пред-расположенности и некоторые иммунологические механизмы хронической крапивницы у детей. Показано, что тучным клеткам и базофилам принадлежит центральная роль в патогенезе всех форм. В ходе воспалительных реакций при хроническом течении крапивницы происходит стимуляция про-дукции таких цитокинов, как CCL2, CХCL8, IL-1, IL-4, IL-6, IL-10, IL-13, IL-17. Активация туч-ных клеток и базофилов реализуется через специфические рецепторы на мембране клеток. Особое место занимает аутоиммунная крапивница, в патогенезе которой участвуют анти-FCεRIα антитела или аутоантитела к IgE, оказывающие гистамино-высвобождающее действие за счет перекрестного связывания α-цепей высокоаффинного IgE рецептора или перекрестного связывания фиксирован-ных на тучных клетках IgE. Дегрануляция базофилов сопровождается появлением активационных молекул -СD203с, CD63. Экспрессию СD203с ряд авторов считает косвенным признаком аутоим-мунного процесса, при наличии положительного теста с аутосывороткой. Повышение экспрессии лиганда CD40L на поверхности активированных Т-лимфоцитов свидетельствует об усилении сигна-лов для активации В-лимфоцитов и синтеза аутоантител.Ключевые слова: хроническая крапивница, цитокины, базофилы, CD203c

show abstract

IL-31 a TH2 Cytokine Involved in Immunity and Inflammation

Cited by 24 publications

References 34 publications

T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis

T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis

Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis

Chronic Urticarial in Childhood. Immune Pathology of Chronic Urticarial in Children (Part I)

Contact Info

Product

Resources

About